 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 01, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that...

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

This indicator may be signaling that ORIC's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Oric Pharmaceuticals (ORIC, $6.53) entered Downtrend as Momentum indicator drops below 0 level on Nov 15, 2023

Oric Pharmaceuticals (ORIC, $6.43) entered Downtrend as Momentum indicator drops below 0 level on Nov 09, 2023

SOUTH SAN FRANCISCO and SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address...

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

ORIC's Cash and Investments Reach $256.2 Million, R&D Expenses Increase to $22.4 MillionRelated Stocks: ORIC...

ORIC Pharmaceuticals Inc (ORIC) Reports Q3 2023 Financial Results and Operational Updates

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Oric Pharmaceuticals reports Q3 EPS (44c), consensus (46c)

Presented initial Phase 1b data for ORIC-114 in patients with EGFR and HER2 Exon 20 mutated NSCLC demonstrating potential best-in-class profile Initial Phase 1b data for ORIC-533 in patients with...

ORIC Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 03, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that...

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that...

ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC-533 in Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting

In trading on Thursday, shares of Oric Pharmaceuticals Inc (ORIC) crossed above their 200 day moving average of 6.34, changing hands as high as 7.04 per share. Oric Pharmaceuticals Inc...

Oric Pharmaceuticals (ORIC) Shares Cross Above 200 DMA

Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.

Watchers	517
52-Wk Low	$2.91
52-Wk High	$9.79

Market Cap	$430.96M
Volume (M)	412,571.00
52-Wk High	$9.79
52-Wk Low	$2.91

Current Price	$8.27
Prev Close	$7.90
Open	$7.90
Dividend Yield	0.00%
50-Day Moving Average	$6.52
Beta	0.90
Avg. Volume	397,905.29
PE Ratio	-4.14

52-Week High	$9.79
52-Week Low	$2.91
Market Capitalization	$430.96M
EPS	-$2.00
Price to Book	1.82
Revenue Per Employee	N/A
Enterprise Value/EBITDA	-1.22

ORIC ORIC Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals